Clinical trial
A Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
NCT00646542 is registered in ClinicalTrials.gov with Novartis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
- Lead sponsor
- Novartis
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2005
- Completion date
- Not reported
- Enrollment
- 525 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.